Skip to content

Study · Randomized controlled trial · n = 206 · 2012

1 result

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.

Montaldo P, Tafuro L, Rea M, Narciso V, Iossa AC, Del Gado R

BJU international7 Feb 2012Cited by 38 (Europe PMC)

PMID22313792 (opens in a new tab)DOI10.1111/j.1464-410x.2011.10918.x (opens in a new tab)PepBankPUB-22313792
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with monosymptomatic nocturnal enuresis, response did not significantly differ between desmopressin 120 µg and 240 µg.

    In plain wordsIn children with bedwetting, response did not significantly differ between desmopressin 120 µg and 240 µg.

    Peptide
    Desmopressin
    Outcome
    No significant changeEnuresis response
    Study

    n = 206

    Comparator
    240 µg desmopressin
    Outcome group
    Enuresis · Kidney and urinary
    Studied dose
    120 µg · oral melt · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the 120 µg and 240 µg patients in terms of response.
    2 context sentences
    Summary · context
    Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males.
    Summary · context
    The patients were randomly divided into two groups: the first group was given oral melt 120 µg and the second group 240 µg, for 2 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.